Surrey M. Walton

Surrey M. Walton

Auto-generated profile, based on publicly available information

Surrey M. Walton

Managing Partner, Second City Outcomes Research LLC, Oak Park, IL, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
JAJuan G Ariza
Juan G Ariza
SWSurrey M. Walton
Surrey M. Walton
MSMauricio Sanabria
Mauricio Sanabria
ABAlfonso Bunch
Alfonso Bunch
JVJasmin Vesga
Jasmin Vesga
ARAngela Rivera
Angela Rivera
Background: The benefits of automated peritoneal dialysis (APD) have been established, but patient adherence to treatment remains a concern. Remote patient monitoring (RPM) programs are a potential solution; however, the cost implications are not well established. This study modeled, from the payer perspective, expected net costs and clinical consequences of a novel RPM program in Colombia. Methods: Amarkov model was used to project costs and clinical outcomes for APD patients with and without RPM. Clinical inputs were directly estimated from Renal Care Services data or taken from the literature. Dialysis costs were estimated from national fees. Inpatient costs were obtained from a recent Colombian study. The model projected overall direct costs and several clinical outcomes. Deterministic and probabilistic sensitivity analyses (DSA and PSA) were also conducted to characterize uncertainty in the results. Results: The model projected that the implementation of an RPM program costing US$35 per month in a cohort of 100 APD patients over 1 year would save US$121,233. The model also projected 31 additional months free of complications, 27 fewer hospitalizations, 518 fewer hospitalization days, and 6 fewer peritonitis episodes. In the DSA, results were most sensitive to hospitalization rates and days of hospitalization, but cost savings were robust. The PSA found there was a 91% chance for the RPM program to be cost saving. Conclusion: The results of the model suggest that RPM is cost-effective in APD patients which should be verified by a rigorous prospective cost analysis.

1 February 2004 in Journal of Medical Systems
Verified
Journal Article
Closed access
PDF file
SWSurrey M. Walton
Surrey M. Walton

1 October 2004 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
GSGlen T Schumock
Glen T Schumock
JBJuan C Blackburn
Juan C Blackburn
ENEdith A Nutescu
Edith A Nutescu
SWSurrey M. Walton
Surrey M. Walton
JFJamie M Finley
Jamie M Finley
RLRichard K Lewis
Richard K Lewis
BACKGROUND: Anticoagulants are widely used and represent a class of drugs that are problem-prone and have a high potential for adverse patient outcomes. As such, these drugs may be amenable to the use of prescribing guidelines. However, relatively little has been published on the effect of such guidelines on clinical outcomes or costs of care. OBJECTIVE: To assess whether guidelines improve the appropriateness of prescribing, clinical outcomes, and costs associated with use of anticoagulants in a sample of community hospitals in the US. METHODS: A retrospective analysis was performed of data voluntarily collected by 15 hospitals before (July—September 2001) and after (March—May 2002) implementation of anticoagulant prescribing guidelines. Statistical analyses of both patient- and hospital-level variables were conducted. RESULTS: Implementation of the guidelines resulted in a significant increase in the proportion of anticoagulants that were prescribed appropriately (59.8% vs 86.9%; p < 0.001). The guidelines also resulted in a shift in the type of anticoagulants prescribed (decreased use of unfractionated heparin and increased use of low-molecular-weight heparins). There was suggestive evidence, although not statistically significant, that the guidelines resulted in fewer anticoagulant-associated adverse events (total bleeding RR 0.71) and lower costs (savings of $56.15 per patient per day). CONCLUSIONS: While limitations existed with the study design, sufficient benefits were identified to warrant hospitals to consider use of these or similar guidelines on a routine basis. Clearly, additional study in this area would be useful.

Verified
Journal Article
Open access
SWSurrey M. Walton
Surrey M. Walton
WMWilson Mayorga
Wilson Mayorga
ANAngela Rodríguez Narváez
Angela Rodríguez Narváez
MCMaria Alejandra Chavez
Maria Alejandra Chavez
NGNatalia Cortés Guesguán
Natalia Cortés Guesguán
LPLudy Alexandra Parada
Ludy Alexandra Parada
Background: Like many developing countries, Colombia faces difficulties in financing health-care services as well as programs for health promotion and health education and there is evidence that its health-care system is underperforming.